Biogen should cost the cost of its spinal muscular atrophy drug Spinraza by roughly 83 percent, according to a recent report released by the Institute for Clinical and Economic Review (ICER), and recommended a $900,000 to $1.5 million price tag for Novartis’ Zolgensma, a drastically smaller price tag than what executives had floated in the past.
According to a FiercePharma report, ICER recommends a $72,000-$130,000 price tag for the first year of treatment of Spinraza, and between $36,000-$65,000 for each consecutive year.
AveXis President Dave Lennon floated a $4 million – $5 million price for Zolgensma. AveXis originally created the drug prior to Novartis’ acquisition of the company.
A Biogen spokeswoman tells FiercePharma that ICER’s report misses the mark as it doesn’t factor in the “significant difference in robustness and quality of evidence for Spinraza as compared to Zolgensma.”